Re: ZHCLF up 290% to $0.16...question
in response to
by
posted on
Dec 14, 2020 04:13PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
At this point , all I care is that Zenith Managment is working to finalize a buyout or major partnership deal with a BP. All this confusion will take care of its self after that i would assume